rasH2™ mouse

Random Transgenic

rasH2™ Random Transgenic Mouse Model

  • Model #
  • Genotype
  • Nomenclature
  • 1178-F
  • 1178-M
  • 1178-F
  • 1178-M

Assess Your Small Molecule Drug for Carcinogenicity Faster and at a Lower Cost

New guidelines condense overall carcinogenicity assessment timelines significantly for compounds which receive a two-year rat study waiver. Assess carcinogenic risk in 6 months vs. 2 years.

Faster Testing Means:

  • Faster time to market with new drugs
  • Lower costs
  • Quicker answers on your compounds
  • Fewer animals dosed for a shorter period of time
  • Significantly lower risk of spontaneous tumors, reducing the incidence of false positives

The gold standard for carcinogenicity testing in vivo

  • A rapid, cost-effective, and sensitive carcinogenicity testing model for detection of nongenotoxic and genotoxic carcinogens.
  • Accepted by the Food & Drug Administration (FDA), European Medicines Agency (EMA), National Medical Products Administration (NMPA), and other regulatory agencies for use in carcinogenicity testing under the International Conference on Harmonisation (ICH) S1B(R1) Guideline.
  • New Weight of Evidence (WoE) criteria enables more drug compounds to forego the 2-year rat study, thereby decreasing testing overall timelines by opting for a 6-month rasH2™ mouse study.
  • Substantial phenotypic background data demonstrate that rasH2™ mice have an extremely low incidence of spontaneous tumors at typical testing ages.
  • More rapid onset and higher incidence of tumors after treatment with either genotoxic or non-genotoxic compounds.
  • Carries a transgenic copy of the human HRAS proto-oncogene in addition to the endogenous murine Ras genes.
  • Sold with full research use rights and are readily available in typical study quantities.
  • In Japan, contact CLEA Japan, Inc. for purchase of rasH2™ mice.
  • Please note that the model nomenclature has been updated. The CIEA designation for the rasH2™ model, CB6F1/Jic-TgrasH2@Tac was used previously.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:

BALB/cBy x C57BL/6 F1 Hybrid Background


The rasH2™ mouse was developed in the laboratory of Tatsuji Nomura of the Central Institute for Experimental Animals (CIEA) in Kawaski, Japan. The model was created by microinjecting the human c-Ha-ras gene into C57BL/6 x DBA/2 zygotes. Hybrid transgenes were constructed from two human HRAS (c-Ha-ras) genes isolated from malignant melanoma and bladder carcinoma tumors. The transgene integrated into the murine transgenic genome as 3* copies in tandem array. The resultant mice were backcrossed to C57BL/6J. Taconic received original stock in March 2000 and the line is genetically refreshed at least every five years. Taconic has received original stock for refresh in 2005, 2012, 2016, and 2020. The mice were derived by embryo transfer and are maintained by intercrossing C57BL/6JJic-Tg(HRAS)2Jic hemizygous male mice with BALB/cByJJic female mice, therefore rasH2-Tg and rasH2-Wt are littermates.


Carries Nnt mutation


Black Agouti



Initial Publication:

  • Saitoh A, Kimura M, Takahashi R, Yokoyama M, Nomura T, Izawa M, Sekiya T, Nishimura S, Katsuki M. (1990) Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene, 5(8):1195-1200.
  • *Suemizu H, et al. (2004) Exp. Anim. 53 (5) 463-466.

Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions for Taconic Models, Products and Services and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic.
  • The Models will be used for research purposes only.
  • The Models will not be bred or cross-bred except to obtain embryos or fetuses required for research purposes unless additional rights have been granted in writing by Taconic.
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Non-profit purchasers may not use this Model and/or biological materials derived from it in sponsored research or contract research studies unless it is purchased at the for-profit price.

Welcome! Tell us a little about yourself